Abstract:
This intricate case report details an exceptionally rare incidence of ovarian metastasis originating from a primary lung adenocarcinoma (LUAD). The relative rarity of this metastatic pathway in medical literature indicates significant diagnostic challenges. This patient was initially found to have both the ovarian tumor and lung nodule and they were originally considered independent primary tumors, derived from radiological interpretations and biomarker profiling. Nevertheless, subsequent postoperative histopathological and immunohistochemical staining evaluations identified ovarian tumors as invasive adenocarcinoma metastasized from lung. The lung and ovary tumor both showed marked anaplastic lymphoma kinase gene (ALK) protein expression by immunohistochemistry. The molecular pathologic genetic testing for lung tumor also revealed ALK rearrangement positive. The complexity of this case underscores the essentiality of maintaining a high degree of diagnostic vigilance, particularly when confronting synchronous tumors. In addition, immunohistochemical staining plays an important role in diagnosing the ovarian neoplasm\'s metastatic nature and determining the primary site of metastatic adenocarcinoma. For lung cancer with ovary metastasis patients, the adopting an adaptable treatment approach responsive to evolving diagnostic evidence can improve the accuracy of diagnosis and avoid excessive treatment of patients.
摘要:
这个复杂的病例报告详细介绍了原发性肺腺癌(LUAD)引起的卵巢转移异常罕见的发生率。这种转移途径在医学文献中的相对罕见性表明了重大的诊断挑战。该患者最初被发现患有卵巢肿瘤和肺结节,最初被认为是独立的原发性肿瘤。来自放射学解释和生物标志物分析。然而,随后的术后组织病理学和免疫组织化学染色评估将卵巢肿瘤鉴定为从肺转移的浸润性腺癌.通过免疫组织化学,肺和卵巢肿瘤均显示出明显的间变性淋巴瘤激酶基因(ALK)蛋白表达。肺肿瘤的分子病理基因检测也显示ALK重排阳性。此案的复杂性凸显了保持高度诊断警惕的必要性,特别是面对同步肿瘤时。此外,免疫组织化学染色在诊断卵巢肿瘤的转移性质和确定转移性腺癌的原发部位中起着重要作用。对于有卵巢转移的肺癌患者,采用适应不断发展的诊断证据的适应性治疗方法可以提高诊断的准确性并避免对患者进行过度治疗.